The challenges of implementing CAR-T therapy in CLL
Saad Kenderian, MB, CHB, Mayo Clinic, Rochester, MN, explains the current challenges faced with implementing CAR-T cell therapy in chronic lymphocytic leukemia (CLL) and strategies to overcome these. Dr Kenderian explains how CAR-T therapy is largely unsuccessful in patients with CLL, due to the immunosuppressive microenvironment and intrinsic T-cell defects present in CLL patients. Dr Kenderian also highlights how considering combinational therapy or further engineering CAR-T cells could help to improve the efficacy of CAR-T therapy in this disease. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
No comments found